Dermal replacement - Organogenesis

Drug Profile

Dermal replacement - Organogenesis

Alternative Names: Vitrix™

Latest Information Update: 26 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Organogenesis
  • Developer Novartis; Organogenesis
  • Class
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetic foot ulcer; Wounds

Most Recent Events

  • 23 May 2003 This product is still in active development
  • 08 Aug 2001 Investigation in Diabetic foot ulcer in USA (Intralesional)
  • 01 Mar 2001 Novartis has an exclusive option to license Vitrix from Organogenesis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top